Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Gilead Sciences is betting big on gene editing to improve its cell immunotherapy programs. But rather than embrace CRISPR, Gilead has partnered with Sangamo Therapeutics, a pioneer of an older gene-editing tool called the zinc finger nuclease (ZFN). Sangamo has amassed a large ZFN protein library, allowing it to link ZFNs together to target any site in the genome. Gilead will give Sangamo $150 million up front and up to $3 billion more if Gilead develops 10 or more new therapies.
This article has been sent to the following recipient: